Epival Tablet contains Sodium Valproate 200mg, an anticonvulsant and mood-stabilizing agent primarily indicated for the management of epilepsy and bipolar disorder. Sodium Valproate acts by increasing the availability of gamma-aminobutyric acid (GABA) in the brain, thereby exerting an inhibitory effect on neuronal excitability and preventing seizure activity. Epival is effective in controlling various types of seizures, including generalized tonic-clonic, absence, and complex partial seizures. Additionally, it is utilized in the prophylaxis of migraine headaches and as a mood stabilizer in bipolar affective disorder to reduce the frequency and severity of manic episodes. The tablet should be administered as prescribed by a healthcare professional, with dosing individualized based on the patient’s clinical response and tolerability. Common adverse effects may include gastrointestinal disturbances, weight gain, tremors, and sedation. Rare but serious side effects include hepatotoxicity, pancreatitis, and thrombocytopenia, necessitating regular monitoring of liver function tests and blood counts during therapy. Epival is contraindicated in patients with known hypersensitivity to valproate, significant hepatic impairment, or urea cycle disorders. Caution is advised during pregnancy due to potential teratogenicity. Patients should avoid abrupt discontinuation to prevent seizure exacerbation.